The Supreme Court's ruling in the Amgen v Sandoz case may hasten the arrival of lower-cost biosimilar versions of biologics in the clinic, potentially saving billions of dollars in health care spending.
Cancer Therapy Advisor asked Filippo Montemurro, MD, to place recent findings in context with respect to when T-DM1 might be best indicated.
Vaccines targeting multiple myeloma antigens offer a promising therapeutic approach by helping the immune system to fight off cancer cells.
Several presentations demonstrated that abemaciclib provides clinical benefit for women with HR+/HER2-negative breast cancer who progress on or are resistant to endocrine therapy.
Targeted and immunotherapeutic approaches are poised to change how sarcoma will be treated in the future. Trials are being used to match tumors with appropriate treatment choices.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Yoga Improves Sleep Disorders, Fatigue in Patients With Cancer
- Aldoxorubicin Improves Outcomes in Relapsed/Refractory Sarcoma
- Cryosurgery: The Future of Breast Cancer Treatment?
- Nivolumab With Ipilimumab May Negate Need for Whole Brain Radiotherapy in Melanoma With Brain Metastases
- Green Tea and Cancer
- Midostaurin Plus Chemotherapy Prolongs Survival in AML With FTL3 Mutation
- MRI Imaging in Adjunct With Mammograms Improves Secondary Breast Cancer Detection
- FDA Approves Subcutaneous Rituximab and Hyaluronidase Human for Blood Cancers
- FDA Approves Dabrafenib and Trametinib for BRAFV600E-mutant NSCLC
- First-line Nivolumab Fails To Prolong Survival in Stage IV NSCLC